Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
16.07
-0.43 (-2.61%)
At close: Jul 3, 2025, 1:00 PM
16.24
+0.17 (1.06%)
After-hours: Jul 3, 2025, 3:50 PM EDT
Telix Pharmaceuticals Revenue
In the year 2024, Telix Pharmaceuticals had annual revenue of 783.21M AUD with 55.85% growth. Telix Pharmaceuticals had revenue of 209.62M in the quarter ending December 31, 2024, with 48.82% growth.
Revenue (ttm)
783.21M AUD
Revenue Growth
+55.85%
P/S Ratio
11.10
Revenue / Employee
1,887,246 AUD
Employees
415
Market Cap
5.38B undefined
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 783.21M | 280.66M | 55.85% |
| Dec 31, 2023 | 502.55M | 342.45M | 213.90% |
| Dec 31, 2022 | 160.10M | 152.50M | 2,007.64% |
| Dec 31, 2021 | 7.60M | 2.38M | 45.71% |
| Dec 31, 2020 | 5.21M | 1.73M | 49.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
TLX News
- 11 days ago - Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT - GlobeNewsWire
- 14 days ago - Telix Precision Medicine Announces AlFluor Radiochemistry Platform - GlobeNewsWire
- 14 days ago - Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025 - GlobeNewsWire
- 4 weeks ago - Telix Investor Day in New York City on June 11, 2025: Presenting KOLs - GlobeNewsWire
- 7 weeks ago - Telix Pharmeceuticals: Imaging Biomarkers Paving The Way For Theranostics - Seeking Alpha
- 2 months ago - Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy - GlobeNewsWire
- 2 months ago - Telix's Illuccix PSMA-PET Imaging Agent Approved in France - GlobeNewsWire
- 2 months ago - Telix Reports US$186M Q1 Revenue, Up 62% YOY - GlobeNewsWire